EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Population Pharmacokinetics and Exposure‐Response Analyses for Ubrogepant Efficacy and Safety in the Acute Treatment of Migraine: Analysis of Phase 1–3 Studies

Sven Stodtmann, Lucia Siovitz, Heiko Babel, Ramesh R Boinpally

The Journal of Clinical Pharmacology · 2026-06 · 66 (6)

DOI: 10.1002/jcph.70175 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 29.05.2026. Verfasst von Sven Stodtmann und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Pyridines, Pyrroles, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A population pharmacokinetic (popPK) model was developed for ubrogepant using data from 10 Phase 1, 1 Phase 2, and 2 Phase 3 studies. The data were described by a 2‐compartment model with linear elimination and transit compartment absorption. Formulation, food intake, race, gender, and hepatic impairment had a statistically significant impact on ubrogepant PK. Significant exposure‐response relationships were found for 2 h pain relief and pain freedom, and 24 h sustained pain relief and sustained pain freedom. Ubrogepant significantly improved the symptoms of phonophobia and photophobia, and the most bothersome migraine symptom, with a modest trend with ubrogepant dose. A Phase 3 study evaluating ubrogepant use during the prodrome was incorporated into the popPK model, and the mean transit time and inter‐individual variability were re‐estimated. Exposure‐response analysis across multiple endpoints in the prodrome study (including absence of moderate/severe headache within 24 or 48 h, absence of headache of any intensity within 24 h, and ability to function normally within 24 h) showed a treatment effect with improved outcomes after receiving ubrogepant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersPyridinesPyrrolesModels, BiologicalHumansFemaleMaleDose-Response Relationship, DrugTreatment OutcomeClinical Trials, Phase I as TopicClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

CGRP receptor antagonistexposure‐responsemigrainepopulation pharmacokineticsprodromeubrogepant

Substanzen

ubrogepantPyridinesPyrroles

Autor:innen und Institutionen

  • Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA.
  • Clinical Pharmacology, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany.

Zitieren

APA

Stodtmann, S., Siovitz, L., Babel, H., & Boinpally, R. R. (2026). Population Pharmacokinetics and Exposure‐Response Analyses for Ubrogepant Efficacy and Safety in the Acute Treatment of Migraine: Analysis of Phase 1–3 Studies. The Journal of Clinical Pharmacology, 66(6). https://doi.org/10.1002/jcph.70175

Vancouver

Stodtmann S, Siovitz L, Babel H, Boinpally RR. Population Pharmacokinetics and Exposure‐Response Analyses for Ubrogepant Efficacy and Safety in the Acute Treatment of Migraine: Analysis of Phase 1–3 Studies. The Journal of Clinical Pharmacology. 2026;66(6). doi:10.1002/jcph.70175

BibTeX
@article{Stodtmann2026,
  author = {Stodtmann, Sven and Siovitz, Lucia and Babel, Heiko and Boinpally, Ramesh R},
  title = {Population Pharmacokinetics and Exposure‐Response Analyses for Ubrogepant Efficacy and Safety in the Acute Treatment of Migraine: Analysis of Phase 1–3 Studies},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  volume = {66},
  number = {6},
  doi = {10.1002/jcph.70175}
}
Kostenlos starten →